Saturday, April 19, 2014

Zacks ups GeneNews price target to $3

Zacks ups GeneNews price target to $3

March 6, 2014 by · Leave a Comment 

Tweet Zacks Investment Research has raised its price target for “outperform-rated” GeneNews (TSX:GEN) to $3 from $2, saying revenue growth will accelerated in 2014 and beyond from a recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL). Shares of GeneNews closed at $1.09 on Wednesday. “Specifically, we estimate revenue from IDL will be $2.6-million [in […]

GeneNews JV in U.S.-wide rollout of ColonSentry, adds new test

GeneNews JV in U.S.-wide rollout of ColonSentry, adds new test

January 21, 2014 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) recently formed joint venture, Innovative Diagnostic Laboratory, or IDL, is initiating the full-scale rollout of the ColonSentry test throughout the U.S. and adding EarlyCDT-Lung – a simple blood test that aids physicians in risk assessment and the early detection of lung cancer in high-risk, asymptomatic patients – to its offering. “I am pleased […]

In conversation with James Howard-Tripp

In conversation with James Howard-Tripp

November 26, 2013 by · Leave a Comment 

Tweet As executive chairman of GeneNews (TSX:GEN; OTC:GNWSF), James Howard-Tripp is a veteran of pharma and biotech management and company creation, which included a long stint as CEO of Labopharm, where he oversaw the development and approval of three products and the launch of two, with the lead product marketed in 19 countries. A longtime member […]

GeneNews provides IDL jv progress update, appoints director

GeneNews provides IDL jv progress update, appoints director

November 14, 2013 by · Leave a Comment 

Tweet In its Q3 results release, GeneNews (TSX:GEN) provided a progress update and announced the appointment of Floyd C. Dent to its Board. In a statement, executive chairman James Howard-Tripp said start-up operations at Innovative Diagnostic Laboratory’s (IDL) Richmond, VA lab, which were initiated in the third quarter, have gone smoothly. “Soon after successfully obtaining CLIA […]

Zachs starts GeneNews at outperform

Zachs starts GeneNews at outperform

July 5, 2013 by · Leave a Comment 

Tweet Zachs Investment Research has initiated coverage of GeneNews (TSX:GEN) with an “outperform” rating and 12-month price target of $3.50, saying the company’s revenue will accelerate in coming years due to a focused marketing strategy and new product offerings. The stock closed at 77 cents on Thursday. “Based on the company’s strong fundamentals, we think […]

GeneNews in JV; to launch ColonSentry test throughout US

GeneNews in JV; to launch ColonSentry test throughout US

July 2, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=0mzb8_cDcEg’]

Tweet GeneNews (TSX:GEN) has formed a joint venture with two private American companies, Health Diagnostic Laboratory, and a sales organization with national capabilities,  to establish an accredited clinical laboratory called Innovative Diagnostic Laboratory (IDL). IDL will initially focus on the development and broader U.S. commercialization of ColonSentry, the world’s first blood test to assess an […]

GeneNews appoints Leslie Auld to board

GeneNews appoints Leslie Auld to board

July 1, 2013 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) CFO and treasurer, Leslie Auld, has been appointed to the board of directors. “Leslie is an accomplished financial professional whose contributions have supported the company’s financial strategy over the last number of years,” chairman Rory Riggs said in a statement. “I am pleased to welcome her to the board, and look forward […]

Exact Sciences’ data disappoints analysts; highlights differences with GeneNews’ test

Exact Sciences’ data disappoints analysts; highlights differences with GeneNews’ test

April 18, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=AcbKNlrpKLU’]

Tweet Shares of Exact Sciences (NASDAQ:EXAS) plummeted as much as 30% on heavier than normal trading volumes today after the company released a preliminary analysis of its DeeP-C pivotal trial with its Cologuard colorectal cancer screening test.   The stock recovered somewhat later in the day, closing down $1.14 to $8.84. Exact Sciences’ test, which identifies abnormal […]

In conversation with Gailina Liew

In conversation with Gailina Liew

January 22, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=0mzb8_cDcEg’]

Tweet As president and COO of GeneNews (TSX:GEN), Gailina Liew established the initial intellectual property strategy and organizational infrastructure for the company over the past dozen years. More recently, she has led the commercialization effort for ColonSentry, a new patient friendly blood test to assess an individual’s current risk of having colorectal cancer. ColonSentry is […]

GeneNews implements share consolidation

GeneNews implements share consolidation

December 24, 2012 by · Leave a Comment 

Tweet Common shares of GeneNews (TSX:GEN) will be posted for trading at the opening today on a one-for-six consolidated basis. The consolidation was approved by the shareholders on April 26, 2012 and announced on Dec. 7. There will be 33,744,883 shares outstanding now. If a shareholder becomes entitled to a fractional share, it will be […]

Next Page »

Google+